s with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.
• Comparison of lopinavir/ritonavir vs. lopinavir/ritonav